Mark E. Robson

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT072: Novel targeting of the microenvironment to decrease metastatic recurrence of high-risk TNBC: A randomized phase II study of tetrathiomolybdate (TM) plus capecitabine in patients with breast cancer at high risk of recurrence

  Cancer Research · 2026-04-17

• CLO26-115: Association Between Geriatric Assessment Variables and Treatment Completion in Older Adults With Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy and Immunotherapy: The MSKCC Experience

  Journal of the National Comprehensive Cancer Network · 2026-03-27

• Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial

  Annals of Oncology · 2025-12-19 · 3 citations

• Supplemental Table 4 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy

  Clinical Cancer Research · 2025-12-17

• Data from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 5 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Materials and Methods from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 6, Supplemental Table 7, Supplemental Figure 1, and Supplemental Figure 2 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

  2025-11-26

• Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

  2025-11-26

• Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

  2025-11-26

• Figure S2 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Figure S1 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Figure S4 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Figure S6 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Figure S3 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Figure S5 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25

• Figure S7 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects

  2025-11-25